The most directly relevant evidence for the executive population comes from studies examining creatine supplementation under conditions of sleep insufficiency: the precise conditions most founders and CEOs regularly encounter. Published research found that creatine supplementation significantly attenuated the decline in cognitive task performance, mood, and balance following 24 hours of sleep deprivation compared to placebo. The mechanism is straightforward: sleep deprivation depletes phosphocreatine stores in the brain; supplementation maintains higher baseline stores and therefore preserves more of the buffer capacity that acute cognitive demands draw on.

A meta-analysis examining the effects of creatine supplementation on cognitive performance across multiple studies found significant benefits specifically in conditions of metabolic stress, including sleep deprivation, oxygen insufficiency, and sustained cognitive demand, with more modest effects in well-rested, unchallenged individuals. This pattern is precisely what the phosphocreatine mechanism predicts: creatine provides the most benefit when the energy system it supports is under strain. Which is precisely the condition in which executive performance is most consequential.

Dietary creatine is obtained primarily from animal protein, specifically red meat and fish. Individuals with low or absent meat consumption have lower baseline muscle and brain creatine stores, and show the largest cognitive improvements from supplementation. In populations with adequate dietary creatine intake, the magnitude of benefit is smaller but still present under high-load conditions. For executives who travel frequently, eat irregularly, or maintain lower animal protein intake, the baseline deficit argument is directly relevant.

Form: Creatine monohydrate, not creatine ethyl ester, not buffered creatine, not proprietary variants that carry a price premium without a corresponding evidence premium. Monohydrate is the form used in virtually all the cognitive research and the form with the most established bioavailability and safety record.

Dose: 3 to 5 grams daily. No loading phase is required for cognitive performance purposes. Consistency of daily intake is the relevant variable, not timing.

Context: As part of a complete performance nutrition framework, not as a standalone intervention. Creatine addresses bioenergetic resilience. It does not address sleep architecture, cortisol rhythm, micronutritional deficiencies, or the metabolic dysfunctions that the rest of this series covers. It occupies a specific and important gap in the performance stack. It does not fill the whole stack.

Beyond the acute cognitive performance case, the longitudinal evidence for creatine as a neuroprotective intervention represents an asymmetric bet: a low-cost, low-risk intervention with mounting evidence of protection against the cognitive decline trajectories that are amongst the most significant risks to both individual longevity and organisational continuity. Creatine reduces oxidative stress in neural tissue, supports mitochondrial function, the primary site of age-related cognitive decline at the cellular level, and has demonstrated protective effects in animal models of neurodegeneration. Preliminary human evidence suggests benefit in populations at elevated risk of cognitive decline. For the executive already thinking about their biological age and the capital they carry into the next decade, the neuroprotective case is not speculative. It is a structural hedge against a measurable risk, at a cost that is negligible relative to every other intervention in the longevity and performance space.